Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
SM

WKN: A41WY9 | ISIN: US81256L3024 | Ticker:
NASDAQ
20.11.26 | 18:50
0,923 US-Dollar
-12,06 % -0,127
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SEASTAR MEDICAL HOLDING CORPORATION Chart 1 Jahr
5-Tage-Chart
SEASTAR MEDICAL HOLDING CORPORATION 5-Tage-Chart

Aktuelle News zur SEASTAR MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SEASTAR MEDICAL Aktie jetzt für 0€ handeln
12.11.SeaStar Medical Holding Corp - 10-Q, Quarterly Report-
12.11.SeaStar Medical Holding Corp - 8-K, Current Report-
12.11.Seastar Medical anticipates NEUTRALIZE-AKI enrollment completion by midyear 2027 while preparing modular PMA submissions3
11.11.Earnings Call: SeaStar Medical übertrifft Umsatzerwartungen im dritten Quartal 2026 - EPS verfehlt Prognose2
11.11.SeaStar Medical Holding Q3 2026 Earnings Call Transcript2
11.11.SeaStar Medical Holding GAAP EPS of -$1.03 misses by $0.08, revenue of $0.64M beats by $0.14M1
11.11.SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates1
04.11.SeaStar Medical to Report Third Quarter Financial Results on November 11, 20266
03.11.FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients3
03.11.SeaStar Medical Holding Corp - 8-K, Current Report1
22.10.SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE SAVE Registry Analysis in Pediatric Sepsis-Associated AKI4
14.10.SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award2
07.10.FDA grants breakthrough device status to SeaStar for sepsis therapy2
07.10.FDA erteilt Sepsis-Therapie von SeaStar den Status "Breakthrough Device"3
07.10.FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition218Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER...
► Artikel lesen
05.10.SeaStar Medical Holding Corp - 8-K, Current Report1
02.10.SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 20261
01.10.New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI)1
29.09.SeaStar Medical CMO to present at pediatric therapy conference1
24.09.SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy2
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1